Search

Displaying results 1211 - 1220 of 10000 in total
  1. Drug

    Mianserin

    go.drugbank.com/drugs/DB06148
    ApprovedWithdrawn

    Mianserin was previously available internationally, however in most markets it has been phased out in favour of [mirtazapine].

    Products: MIANSERIN-NEURAX 10 MG, TOLVON TABLET 10 MG, 30 ADET
  2. Drug

    Gadobenic acid

    go.drugbank.com/drugs/DB00743
    ApprovedInvestigational

    [A1139] Gadobenate dimeglumine was approved by the FDA in November 2004 under the brand name MultiHance.[A263166] … Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver.

    Mixtures: MULTIHANCE INJECTION 10 ML, MULTIHANCE INJECTION 10 MLProducts: MULTIHANCE INJECTION 20 ML, MULTIHANCE TEK DOZLUK IV ENJEKSIYONLUK COZELTI ICEREN FLAKON, 10 ML
  3. Drug

    Pancuronium

    go.drugbank.com/drugs/DB01337
    Approved

    As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.

    Products: BROMURO DE PANCURONIO 4 MG/2 ML, BROMURO DE PANCURONIO 2 MG/ML
  4. Drug

    Asciminib

    go.drugbank.com/drugs/DB12597
    ApprovedInvestigational

    [L38995,A241055] Asciminib received FDA approval on October 29, 2021 (Scemblix, Novartis AG).[L39000] … Existing inhibitors of ABL compete at the ATP binding sites of these proteins and can be classified into those that target the active conformation of the kinase domain ([dasatinib], [bosutinib]) and those

    Products: AZEVAY 20 MG FİLM KAPLI TABLET , 60 ADET, AZEVAY 40 MG FİLM KAPLI TABLET , 60 ADET
  5. Drug

    Cholic Acid

    go.drugbank.com/drugs/DB02659
    ApprovedInvestigational

    It facilitates fat absorption and cholesterol excretion.

    Products: ORPHACOL ® 250 MG, ORPHACOL®50 MG
  6. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    [L4538] It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. … [L4537] It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical trials.

    Products: TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 2 ADET
  7. Drug

    Mecobalamin

    go.drugbank.com/drugs/DB03614
    ApprovedInvestigational

    Mixtures: Medi-10, Prena1 ChewProducts: NEUROCOBAL TABLETS 500 MCG, METHYCOBAL INJECTION 500 mcg/ml
  8. Drug

    Cabotegravir

    go.drugbank.com/drugs/DB11751
    ApprovedInvestigational

    [A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than [dolutegravir],[A227668] which resulted in the development of long acting monthly intramuscular injection

    Products: Vocabria 400 mg/2 ml Enjeksiyonluk Uzatılmış Salımlı Süspansiyon, 1 ADET, Vocabria 600 mg/3 ml Enjeksiyonluk Uzatılmış Salımlı Süspansiyon, 1 ADET
  9. Drug

    Chlordiazepoxide

    go.drugbank.com/drugs/DB00475
    ApprovedIllicit

    It has also been used in the symptomatic treatment of alcohol withdrawal.

    Mixtures: LIBRAX DRAJE, 100 ADET, LIBRAX DRAJE, 500 ADETProducts: BENPINE CAPSULE 10 mg, Medilium Cap 10 10mg
  10. Drug

    Dutasteride

    go.drugbank.com/drugs/DB01126
    ApprovedInvestigational

    However, unlike finasteride, dutasteride is not yet indicated for the treatment of androgenic alopecia although it was demonstrated to be effective in several randomized, double-blind, placebo-controlled … Dutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to

    Mixtures: DUTASTERIDE E TAMSULOSINA DOC, DUTASTERIDE E TAMSULOSINA DOCProducts: DUTASTERIDE EG, AVODART (0.5 MG)